{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:24:32Z","timestamp":1777926272304,"version":"3.51.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10741-021-10159-w","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:02:33Z","timestamp":1630533753000},"page":"1549-1557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinical management of amyloid cardiomyopathy"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8621-1911","authenticated-orcid":false,"given":"Morris M.","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton M.","family":"Kolseth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayna","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"issue":"1","key":"10159_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.amjcard.2019.09.039","volume":"125","author":"B Abraham","year":"2020","unstructured":"Abraham B et al (2020) Meta-analysis comparing torsemide versus furosemide in patients with heart failure. Am J Cardiol 125(1):92\u201399","journal-title":"Am J Cardiol"},{"issue":"6","key":"10159_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2459\/JCM.0000000000000794","volume":"20","author":"JA Miles","year":"2019","unstructured":"Miles JA et al (2019) Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis. J Cardiovasc Med (Hagerstown) 20(6):379\u2013388","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"14","key":"10159_CR3","first-page":"e391","volume":"119","author":"SA Hunt","year":"2009","unstructured":"Hunt SA et al (2009) 2009 focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14):e391-479","journal-title":"Circulation"},{"issue":"9766","key":"10159_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","volume":"377","author":"WT Abraham","year":"2011","unstructured":"Abraham WT et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377(9766):658\u2013666","journal-title":"Lancet"},{"issue":"17","key":"10159_CR5","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","volume":"110","author":"JB Young","year":"2004","unstructured":"Young JB et al (2004) Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110(17):2618\u20132626","journal-title":"Circulation"},{"issue":"5","key":"10159_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"Yusuf S et al (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293\u2013302","journal-title":"N Engl J Med"},{"issue":"5b","key":"10159_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/0002-9343(84)90881-7","volume":"76","author":"TB Levine","year":"1984","unstructured":"Levine TB, Olivari MT, Cohn JN (1984) Hemodynamic and regional blood flow response to captopril in congestive heart failure. Am J Med 76(5b):38\u201342","journal-title":"Am J Med"},{"issue":"4","key":"10159_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1161\/01.CIR.67.4.807","volume":"67","author":"BL Kramer","year":"1983","unstructured":"Kramer BL, Massie BM, Topic N (1983) Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 67(4):807\u2013816","journal-title":"Circulation"},{"issue":"2","key":"10159_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/01.CIR.83.2.523","volume":"83","author":"AR Bengur","year":"1991","unstructured":"Bengur AR et al (1991) Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy. Circulation 83(2):523\u2013527","journal-title":"Circulation"},{"issue":"4","key":"10159_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/anec.12032","volume":"18","author":"M Boldrini","year":"2013","unstructured":"Boldrini M et al (2013) Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis. Ann Noninvasive Electrocardiol 18(4):327\u2013335","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"9","key":"10159_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/thx.37.9.711","volume":"37","author":"BE Griffiths","year":"1982","unstructured":"Griffiths BE et al (1982) Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax 37(9):711\u2013712","journal-title":"Thorax"},{"issue":"2","key":"10159_CR12","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1378\/chest.104.2.618","volume":"104","author":"A Pollak","year":"1993","unstructured":"Pollak A, Falk RH (1993) Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 104(2):618\u2013620","journal-title":"Chest"},{"issue":"13 Pt 1","key":"10159_CR13","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","volume":"55","author":"MA Gertz","year":"1985","unstructured":"Gertz MA et al (1985) Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 55(13 Pt 1):1645","journal-title":"Am J Cardiol"},{"issue":"13 Pt 1","key":"10159_CR14","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/0002-9149(85)90996-8","volume":"55","author":"MA Gertz","year":"1985","unstructured":"Gertz MA et al (1985) Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 55(13 Pt 1):1646","journal-title":"Am J Cardiol"},{"issue":"6","key":"10159_CR15","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","volume":"63","author":"A Rubinow","year":"1981","unstructured":"Rubinow A, Skinner M, Cohen AS (1981) Digoxin sensitivity in amyloid cardiomyopathy. Circulation 63(6):1285\u20131288","journal-title":"Circulation"},{"issue":"2","key":"10159_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","volume":"25","author":"E Muchtar","year":"2018","unstructured":"Muchtar E et al (2018) Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 25(2):86\u201392","journal-title":"Amyloid"},{"key":"10159_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","volume":"133","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP et al (2020) Digoxin use in cardiac amyloidosis. Am J Cardiol 133:134\u2013138","journal-title":"Am J Cardiol"},{"issue":"3","key":"10159_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ana.24725","volume":"80","author":"AJ Loavenbruck","year":"2016","unstructured":"Loavenbruck AJ et al (2016) Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox? Ann Neurol 80(3):401\u2013411","journal-title":"Ann Neurol"},{"issue":"13","key":"10159_CR19","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112(13):2047\u20132060","journal-title":"Circulation"},{"issue":"6","key":"10159_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF02267725","volume":"7","author":"JC Denq","year":"1997","unstructured":"Denq JC et al (1997) Efficacy of compression of different capacitance beds in the amelioration of orthostatic hypotension. Clin Auton Res 7(6):321\u2013326","journal-title":"Clin Auton Res"},{"issue":"7","key":"10159_CR21","doi-asserted-by":"publisher","first-page":"e652","DOI":"10.1212\/WNL.0000000000005994","volume":"91","author":"JL Newton","year":"2018","unstructured":"Newton JL, Frith J (2018) The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. Neurology 91(7):e652\u2013e656","journal-title":"Neurology"},{"issue":"4","key":"10159_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jash.2013.04.006","volume":"7","author":"C Shibao","year":"2013","unstructured":"Shibao C, Lipsitz LA, Biaggioni I (2013) Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens 7(4):317\u2013324","journal-title":"J Am Soc Hypertens"},{"issue":"1","key":"10159_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13256-020-02405-w","volume":"14","author":"AH Ho","year":"2020","unstructured":"Ho AH et al (2020) Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report. J Med Case Rep 14(1):73","journal-title":"J Med Case Rep"},{"key":"10159_CR24","doi-asserted-by":"crossref","unstructured":"Grijalva CG et al (2017)\u00a0Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. J Am Heart Assoc 6(10)","DOI":"10.1161\/JAHA.117.006848"},{"issue":"1","key":"10159_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0735-1097(84)80436-2","volume":"3","author":"RH Falk","year":"1984","unstructured":"Falk RH, Rubinow A, Cohen AS (1984) Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 3(1):107\u2013113","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10159_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/hrt.78.1.74","volume":"78","author":"SW Dubrey","year":"1997","unstructured":"Dubrey SW et al (1997) Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78(1):74\u201382","journal-title":"Heart"},{"issue":"5","key":"10159_CR27","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ehf2.12308","volume":"5","author":"YY Mints","year":"2018","unstructured":"Mints YY et al (2018) Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail 5(5):772\u2013779","journal-title":"ESC Heart Fail"},{"issue":"10","key":"10159_CR28","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126(10):1286\u20131300","journal-title":"Circulation"},{"issue":"18","key":"10159_CR29","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","volume":"119","author":"D Feng","year":"2009","unstructured":"Feng D et al (2009) Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 119(18):2490\u20132497","journal-title":"Circulation"},{"issue":"9","key":"10159_CR30","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","volume":"6","author":"E Donnellan","year":"2020","unstructured":"Donnellan E et al (2020) Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol 6(9):1118\u20131127","journal-title":"JACC Clin Electrophysiol"},{"key":"10159_CR31","unstructured":"Mitrani LR et al (2019) Abstract 14004: atrial fibrillation in transthyretin amyloid cardiomyopathy may present with controlled ventricular response: a retrospective study. Circulation\u00a0140(1):A14004\u2013A14004"},{"issue":"3","key":"10159_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","volume":"26","author":"K Sanchis","year":"2019","unstructured":"Sanchis K et al (2019) Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid 26(3):128\u2013138","journal-title":"Amyloid"},{"issue":"5","key":"10159_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","volume":"73","author":"EA El-Am","year":"2019","unstructured":"El-Am EA et al (2019) Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 73(5):589\u2013597","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10159_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","volume":"13","author":"CR Barbhaiya","year":"2016","unstructured":"Barbhaiya CR et al (2016) Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm 13(2):383\u2013390","journal-title":"Heart Rhythm"},{"issue":"9","key":"10159_CR35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/pace.13992","volume":"43","author":"E Black-Maier","year":"2020","unstructured":"Black-Maier E et al (2020) Catheter ablation of atrial fibrillation in cardiac amyloidosis. Pacing Clin Electrophysiol 43(9):913\u2013921","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"10159_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/europace\/euz314","volume":"22","author":"E Donnellan","year":"2020","unstructured":"Donnellan E et al (2020) Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. Europace 22(2):259\u2013264","journal-title":"Europace"},{"issue":"45","key":"10159_CR37","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1093\/eurheartj\/ehy555","volume":"39","author":"M Brignole","year":"2018","unstructured":"Brignole M et al (2018) A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J 39(45):3999\u20134008","journal-title":"Eur Heart J"},{"issue":"2","key":"10159_CR38","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1023\/A:1009795330454","volume":"2","author":"GN Kay","year":"1998","unstructured":"Kay GN et al (1998) The ablate and pace trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators J Interv Card Electrophysiol 2(2):121\u2013135","journal-title":"APT Investigators J Interv Card Electrophysiol"},{"issue":"12","key":"10159_CR39","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","volume":"5","author":"E Donnellan","year":"2019","unstructured":"Donnellan E et al (2019) No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC Clin Electrophysiol 5(12):1473\u20131474","journal-title":"JACC Clin Electrophysiol"},{"issue":"21","key":"10159_CR40","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","volume":"116","author":"D Feng","year":"2007","unstructured":"Feng D et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420\u20132426","journal-title":"Circulation"},{"issue":"1","key":"10159_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","volume":"28","author":"LR Mitrani","year":"2021","unstructured":"Mitrani LR et al (2021) Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding. Amyloid 28(1):30\u201334","journal-title":"Amyloid"},{"issue":"5","key":"10159_CR42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/hrt.74.5.541","volume":"74","author":"S Dubrey","year":"1995","unstructured":"Dubrey S et al (1995) Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 74(5):541\u2013544","journal-title":"Br Heart J"},{"issue":"2","key":"10159_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2459\/JCM.0000000000000188","volume":"17","author":"G Di Bella","year":"2016","unstructured":"Di Bella G et al (2016) Left atrial function in cardiac amyloidosis. J Cardiovasc Med (Hagerstown) 17(2):113\u2013121","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"2","key":"10159_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/eurheartj\/ehi040","volume":"26","author":"KM Modesto","year":"2005","unstructured":"Modesto KM et al (2005) Left atrial myopathy in cardiac amyloidosis: implications of novel echocardiographic techniques. Eur Heart J 26(2):173\u2013179","journal-title":"Eur Heart J"},{"issue":"10","key":"10159_CR45","first-page":"1128","volume":"18","author":"K Nochioka","year":"2017","unstructured":"Nochioka K et al (2017) Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 18(10):1128\u20131137","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"22","key":"10159_CR46","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1056\/NEJM199211263272205","volume":"327","author":"JF Plehn","year":"1992","unstructured":"Plehn JF, Southworth J, Cornwell GG 3rd (1992) Brief report: atrial systolic failure in primary amyloidosis. N Engl J Med 327(22):1570\u20131573","journal-title":"N Engl J Med"},{"issue":"24","key":"10159_CR47","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","volume":"70","author":"VY Reddy","year":"2017","unstructured":"Reddy VY et al (2017) 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 70(24):2964\u20132975","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10159_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","volume":"91","author":"SW Dubrey","year":"1998","unstructured":"Dubrey SW et al (1998) The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91(2):141\u2013157","journal-title":"QJM"},{"issue":"3","key":"10159_CR49","doi-asserted-by":"publisher","first-page":"e283","DOI":"10.1161\/CIR.0b013e318276ce9b","volume":"127","author":"AE Epstein","year":"2013","unstructured":"Epstein AE et al (2013) 2012 ACCF\/AHA\/HRS focused update incorporated into the ACCF\/AHA\/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 127(3):e283-352","journal-title":"Circulation"},{"issue":"2","key":"10159_CR50","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","volume":"5","author":"AV Kristen","year":"2008","unstructured":"Kristen AV et al (2008) Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 5(2):235\u2013240","journal-title":"Heart Rhythm"},{"issue":"8","key":"10159_CR51","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/clc.20389","volume":"32","author":"A Dhoble","year":"2009","unstructured":"Dhoble A et al (2009) Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol 32(8):E63\u2013E65","journal-title":"Clin Cardiol"},{"issue":"12","key":"10159_CR52","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/eurheartj\/ehp592","volume":"31","author":"G Lin","year":"2010","unstructured":"Lin G, Dispenzieri A, Brady PA (2010) Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. Eur Heart J 31(12):1538\u20131538","journal-title":"Eur Heart J"},{"issue":"7","key":"10159_CR53","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jce.12123","volume":"24","author":"G Lin","year":"2013","unstructured":"Lin G et al (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 24(7):793\u2013798","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"10159_CR54","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","volume":"11","author":"BC Varr","year":"2014","unstructured":"Varr BC et al (2014) Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm 11(1):158\u2013162","journal-title":"Heart Rhythm"},{"issue":"4","key":"10159_CR55","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ejhf.1039","volume":"20","author":"CS Siegismund","year":"2018","unstructured":"Siegismund CS et al (2018) Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur J Heart Fail 20(4):751\u2013757","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10159_CR56","doi-asserted-by":"publisher","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","volume":"9","author":"UA Tahir","year":"2019","unstructured":"Tahir UA et al (2019) Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci Rep 9(1):8552","journal-title":"Sci Rep"},{"issue":"11","key":"10159_CR57","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"8","key":"10159_CR58","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/europace\/euaa094","volume":"22","author":"EJ Kim","year":"2020","unstructured":"Kim EJ et al (2020) Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator. Europace 22(8):1216\u20131223","journal-title":"Europace"},{"issue":"21","key":"10159_CR59","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.jacc.2013.02.046","volume":"61","author":"J Chen","year":"2013","unstructured":"Chen J et al (2013) Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol 61(21):2161\u20132168","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10159_CR60","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00267-2","volume":"30","author":"J Reisinger","year":"1997","unstructured":"Reisinger J et al (1997) Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 30(4):1046\u20131051","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10159_CR61","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/jce.14180","volume":"30","author":"E Donnellan","year":"2019","unstructured":"Donnellan E et al (2019) Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol 30(11):2427\u20132432","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"9058","key":"10159_CR62","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/S0140-6736(96)07015-8","volume":"349","author":"SD Anker","year":"1997","unstructured":"Anker SD et al (1997) Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349(9058):1050\u20131053","journal-title":"Lancet"},{"issue":"7","key":"10159_CR63","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/eurheartj\/ehs381","volume":"34","author":"S F\u00fclster","year":"2013","unstructured":"F\u00fclster S et al (2013) Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 34(7):512\u2013519","journal-title":"Eur Heart J"},{"issue":"1","key":"10159_CR64","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00392-019-01490-2","volume":"109","author":"F Escher","year":"2020","unstructured":"Escher F et al (2020) When and how do patients with cardiac amyloidosis die? Clin Res Cardiol 109(1):78\u201388","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"10159_CR65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13539-010-0008-0","volume":"1","author":"P Rozentryt","year":"2010","unstructured":"Rozentryt P et al (2010) The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle 1(1):35\u201342","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"10159_CR66","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s12170-013-0353-6","volume":"7","author":"G Azhar","year":"2013","unstructured":"Azhar G, Wei JY (2013) New approaches to treating cardiac cachexia in the older patient. Curr Cardiovasc Risk Rep 7(6):480\u2013484","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"5","key":"10159_CR67","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jand.2012.03.012","volume":"112","author":"JV White","year":"2012","unstructured":"White JV et al (2012) Consensus statement of the Academy of Nutrition and Dietetics\/American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). J Acad Nutr Diet 112(5):730\u2013738","journal-title":"J Acad Nutr Diet"},{"issue":"3","key":"10159_CR68","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.cardfail.2013.01.011","volume":"19","author":"M Bakitas","year":"2013","unstructured":"Bakitas M et al (2013) Palliative care consultations for heart failure patients: how many, when, and why? J Card Fail 19(3):193\u2013201","journal-title":"J Card Fail"},{"issue":"2","key":"10159_CR69","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/jpm.2014.0192","volume":"18","author":"AC Sidebottom","year":"2015","unstructured":"Sidebottom AC et al (2015) Inpatient palliative care for patients with acute heart failure: outcomes from a randomized trial. J Palliat Med 18(2):134\u2013142","journal-title":"J Palliat Med"},{"issue":"5\u20136","key":"10159_CR70","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00228-005-0941-6","volume":"61","author":"A Pathak","year":"2005","unstructured":"Pathak A et al (2005) Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. Eur J Clin Pharmacol 61(5\u20136):471\u2013474","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10159_CR71","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/mds.26086","volume":"30","author":"RA Hauser","year":"2015","unstructured":"Hauser RA et al (2015) Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson\u2019s disease (nOH306B). Mov Disord 30(5):646\u2013654","journal-title":"Mov Disord"},{"issue":"4","key":"10159_CR72","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/01.CIR.65.4.819","volume":"65","author":"SM Sobol","year":"1982","unstructured":"Sobol SM, Rakita L (1982) Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation 65(4):819\u2013824","journal-title":"Circulation"},{"issue":"10","key":"10159_CR73","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/bjo.66.10.676","volume":"66","author":"DV Ingram","year":"1982","unstructured":"Ingram DV, Jaggarao NS, Chamberlain DA (1982) Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 66(10):676\u2013679","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10159_CR74","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0002-9343(91)90187-3","volume":"91","author":"MD Trip","year":"1991","unstructured":"Trip MD, Wiersinga W, Plomp TA (1991) Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 91(5):507\u2013511","journal-title":"Am J Med"},{"issue":"5","key":"10159_CR75","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.1840090504","volume":"9","author":"JH Lewis","year":"1989","unstructured":"Lewis JH et al (1989) Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 9(5):679\u2013685","journal-title":"Hepatology"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10159-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-021-10159-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10159-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T08:23:36Z","timestamp":1660811016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-021-10159-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10159"],"URL":"https:\/\/doi.org\/10.1007\/s10741-021-10159-w","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"16 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ahmad Masri has research grants from Pfizer, Akcea, and Ultromics (paid to OHSU) and consulting fees from Eidos, Ionis, Alnylam, Pfizer, Akcea, and Cytokinetics. Other co-authors have no conflict of interest to report.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}